High serum IL-2 levels are predictive of prolonged survival in multiple myeloma

G. Cimino, G. Avvisati, S. Amadori, M. C. Cava, D. Giannarelli, G. D. Di Nucci, V. Magliocca, M. T. Petrucci, G. Poti, C. Sgadari, F. Mandelli

Research output: Contribution to journalArticle

Abstract

In this study we analysed serum IL-2 levels in 61 patients with multiple myeloma (MM). Patients serum IL-2 levels were significantly higher than normal controls. Moreover, higher serum IL-2 levels were associated with a prolonged actuarial survival. In particular, 87% of the MM patients with IL-2 ≥ 10 U/ml are still alive at 5 years while only 13% of the remaining patients with IL-2 ≤ 10 U/ml are alive. The multivariate analysis confirmed these data indicating that high serum IL-2 levels are the most useful predictor index of longer survival in MM patients. Furhermore, among the 50 patients on whom serum beta-2-microglobulin (SB2M) determination was available we observed that all patients with serum IL-2 levels ≥ 10 U/ml had SB2M <6 μg/ml, whereas in patients with serum IL-2 <10 U/ml SB2M ranged from 1.3 to 15 μg/ml. Using these two parameters we were able to identify three groups of patients with different survival duration. Group A (9 patients) defined by serum IL-2 ≥ 10 U/ml and SB2M <6 μg/ml in which all patients are alive; group B (26 patients) characterized by serum IL-2 <10 U/ml and SB2M <6 μg/ml in which 24% of patients are alive and group C (15 patients) characterized by serum IL-2 levels <10 U/ml and SB2M ≥ 6 μg/ml in which the actuarial survival curve drops to O at 2.5 years. A statistically significant difference was observed between groups A and B (p

Original languageEnglish
Pages (from-to)373-377
Number of pages5
JournalBritish Journal of Haematology
Volume75
Issue number3
Publication statusPublished - 1990

Fingerprint

Multiple Myeloma
Interleukin-2
Survival
beta 2-Microglobulin
Serum
Interleukin-10
Multivariate Analysis

ASJC Scopus subject areas

  • Hematology

Cite this

Cimino, G., Avvisati, G., Amadori, S., Cava, M. C., Giannarelli, D., Di Nucci, G. D., ... Mandelli, F. (1990). High serum IL-2 levels are predictive of prolonged survival in multiple myeloma. British Journal of Haematology, 75(3), 373-377.

High serum IL-2 levels are predictive of prolonged survival in multiple myeloma. / Cimino, G.; Avvisati, G.; Amadori, S.; Cava, M. C.; Giannarelli, D.; Di Nucci, G. D.; Magliocca, V.; Petrucci, M. T.; Poti, G.; Sgadari, C.; Mandelli, F.

In: British Journal of Haematology, Vol. 75, No. 3, 1990, p. 373-377.

Research output: Contribution to journalArticle

Cimino, G, Avvisati, G, Amadori, S, Cava, MC, Giannarelli, D, Di Nucci, GD, Magliocca, V, Petrucci, MT, Poti, G, Sgadari, C & Mandelli, F 1990, 'High serum IL-2 levels are predictive of prolonged survival in multiple myeloma', British Journal of Haematology, vol. 75, no. 3, pp. 373-377.
Cimino G, Avvisati G, Amadori S, Cava MC, Giannarelli D, Di Nucci GD et al. High serum IL-2 levels are predictive of prolonged survival in multiple myeloma. British Journal of Haematology. 1990;75(3):373-377.
Cimino, G. ; Avvisati, G. ; Amadori, S. ; Cava, M. C. ; Giannarelli, D. ; Di Nucci, G. D. ; Magliocca, V. ; Petrucci, M. T. ; Poti, G. ; Sgadari, C. ; Mandelli, F. / High serum IL-2 levels are predictive of prolonged survival in multiple myeloma. In: British Journal of Haematology. 1990 ; Vol. 75, No. 3. pp. 373-377.
@article{e253421ab1b84d29acbbd6ab3213f687,
title = "High serum IL-2 levels are predictive of prolonged survival in multiple myeloma",
abstract = "In this study we analysed serum IL-2 levels in 61 patients with multiple myeloma (MM). Patients serum IL-2 levels were significantly higher than normal controls. Moreover, higher serum IL-2 levels were associated with a prolonged actuarial survival. In particular, 87{\%} of the MM patients with IL-2 ≥ 10 U/ml are still alive at 5 years while only 13{\%} of the remaining patients with IL-2 ≤ 10 U/ml are alive. The multivariate analysis confirmed these data indicating that high serum IL-2 levels are the most useful predictor index of longer survival in MM patients. Furhermore, among the 50 patients on whom serum beta-2-microglobulin (SB2M) determination was available we observed that all patients with serum IL-2 levels ≥ 10 U/ml had SB2M <6 μg/ml, whereas in patients with serum IL-2 <10 U/ml SB2M ranged from 1.3 to 15 μg/ml. Using these two parameters we were able to identify three groups of patients with different survival duration. Group A (9 patients) defined by serum IL-2 ≥ 10 U/ml and SB2M <6 μg/ml in which all patients are alive; group B (26 patients) characterized by serum IL-2 <10 U/ml and SB2M <6 μg/ml in which 24{\%} of patients are alive and group C (15 patients) characterized by serum IL-2 levels <10 U/ml and SB2M ≥ 6 μg/ml in which the actuarial survival curve drops to O at 2.5 years. A statistically significant difference was observed between groups A and B (p",
author = "G. Cimino and G. Avvisati and S. Amadori and Cava, {M. C.} and D. Giannarelli and {Di Nucci}, {G. D.} and V. Magliocca and Petrucci, {M. T.} and G. Poti and C. Sgadari and F. Mandelli",
year = "1990",
language = "English",
volume = "75",
pages = "373--377",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "John Wiley & Sons, Ltd (10.1111)",
number = "3",

}

TY - JOUR

T1 - High serum IL-2 levels are predictive of prolonged survival in multiple myeloma

AU - Cimino, G.

AU - Avvisati, G.

AU - Amadori, S.

AU - Cava, M. C.

AU - Giannarelli, D.

AU - Di Nucci, G. D.

AU - Magliocca, V.

AU - Petrucci, M. T.

AU - Poti, G.

AU - Sgadari, C.

AU - Mandelli, F.

PY - 1990

Y1 - 1990

N2 - In this study we analysed serum IL-2 levels in 61 patients with multiple myeloma (MM). Patients serum IL-2 levels were significantly higher than normal controls. Moreover, higher serum IL-2 levels were associated with a prolonged actuarial survival. In particular, 87% of the MM patients with IL-2 ≥ 10 U/ml are still alive at 5 years while only 13% of the remaining patients with IL-2 ≤ 10 U/ml are alive. The multivariate analysis confirmed these data indicating that high serum IL-2 levels are the most useful predictor index of longer survival in MM patients. Furhermore, among the 50 patients on whom serum beta-2-microglobulin (SB2M) determination was available we observed that all patients with serum IL-2 levels ≥ 10 U/ml had SB2M <6 μg/ml, whereas in patients with serum IL-2 <10 U/ml SB2M ranged from 1.3 to 15 μg/ml. Using these two parameters we were able to identify three groups of patients with different survival duration. Group A (9 patients) defined by serum IL-2 ≥ 10 U/ml and SB2M <6 μg/ml in which all patients are alive; group B (26 patients) characterized by serum IL-2 <10 U/ml and SB2M <6 μg/ml in which 24% of patients are alive and group C (15 patients) characterized by serum IL-2 levels <10 U/ml and SB2M ≥ 6 μg/ml in which the actuarial survival curve drops to O at 2.5 years. A statistically significant difference was observed between groups A and B (p

AB - In this study we analysed serum IL-2 levels in 61 patients with multiple myeloma (MM). Patients serum IL-2 levels were significantly higher than normal controls. Moreover, higher serum IL-2 levels were associated with a prolonged actuarial survival. In particular, 87% of the MM patients with IL-2 ≥ 10 U/ml are still alive at 5 years while only 13% of the remaining patients with IL-2 ≤ 10 U/ml are alive. The multivariate analysis confirmed these data indicating that high serum IL-2 levels are the most useful predictor index of longer survival in MM patients. Furhermore, among the 50 patients on whom serum beta-2-microglobulin (SB2M) determination was available we observed that all patients with serum IL-2 levels ≥ 10 U/ml had SB2M <6 μg/ml, whereas in patients with serum IL-2 <10 U/ml SB2M ranged from 1.3 to 15 μg/ml. Using these two parameters we were able to identify three groups of patients with different survival duration. Group A (9 patients) defined by serum IL-2 ≥ 10 U/ml and SB2M <6 μg/ml in which all patients are alive; group B (26 patients) characterized by serum IL-2 <10 U/ml and SB2M <6 μg/ml in which 24% of patients are alive and group C (15 patients) characterized by serum IL-2 levels <10 U/ml and SB2M ≥ 6 μg/ml in which the actuarial survival curve drops to O at 2.5 years. A statistically significant difference was observed between groups A and B (p

UR - http://www.scopus.com/inward/record.url?scp=0025341736&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025341736&partnerID=8YFLogxK

M3 - Article

C2 - 2386771

AN - SCOPUS:0025341736

VL - 75

SP - 373

EP - 377

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 3

ER -